Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Year: 2025
Type: article
Study design: Clinical Trial
Source: NEJM Evidence
Authors: Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Jay L. Patel, Alessandro Rambaldi, William E. Shomali, Stephen T. Oh, Kensuke Usuki, Claire N. Harrison, Ellen K. Ritchie, Luke P. Akard, Juan Carlos Hernández-Boluda, Françoise Huguet, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Aidan Gilmartin, Cheryl Langford, Tracy I. George, Andreas Reiter, Jason Gotlib
Institutions: The University of Texas MD Anderson Cancer Center, Université Paris Cité, Hôpital Saint-Louis, Azienda Ospedaliero-Universitaria Careggi, University of Florence, University of Utah, Huntsman Cancer Institute, ARUP Laboratories (United States), University of Milan, Ospedale Papa Giovanni XXIII, Stanford Medicine, Stanford Cancer Institute, Stanford University, Washington University in St. Louis, Teikyo University, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, NewYork–Presbyterian Hospital, Franciscan Health Indianapolis, Universitat de València, Institut universitaire du cancer de Toulouse Oncopole, Incyte (United States), Heidelberg University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413687643